Recently, under large-scale screening experiments, we found that
sphondin, a
furanocoumarin derivative isolated from Heracleum laciniatum, possessed an inhibitory effect on IL-1beta-induced increase in the level of COX-2
protein and
PGE(2) release in A549 cells. Accordingly, we examined in the present study the action mechanism of
sphondin on the inhibition of IL-1beta-induced COX-2
protein expression and
PGE(2) release in a human pulmonary epithelial cell line (A549). Pretreatment of cells with
sphondin (10-50 microM) concentration-dependently attenuated IL-1beta-induced COX-2
protein expression and
PGE(2) release. The IL-1beta-induced increase in COX-2
mRNA expression was also attenuated by
sphondin (50 microM). The selective
COX-2 inhibitor,
NS-398 (0.01-1 microM), inhibited the activity of the COX-2
enzyme in a concentration-dependent manner, while
sphondin (10-50 microM) had no effect.
Sphondin (50 microM) did not affect the IL-1beta-induced activations of p44/42
MAPK, p38 MAPK, and JNK. Treatment of cells with
sphondin (50 microM) or the
NF-kappaB inhibitor,
PDTC (50 microM) partially inhibited IL-1beta-induced degradation of
IkappaB-alpha in the cytosol and translocation of p65
NF-kappaB from the cytosol to the nucleus. Furthermore, IL-1beta-induced
NF-kappaB-specific
DNA-
protein complex formation in the nucleus was partially inhibited by
sphondin (50 microM) or
PDTC (50 microM). Taken together, we demonstrate that
sphondin inhibits IL-1beta-induced
PGE(2) release in A549 cells; this inhibition is mediated by suppressing of COX-2 expression, rather than by inhibiting COX-2
enzyme activity. The inhibitory mechanism of
sphondin on IL-1beta-induced COX-2 expression may be, at least in part, through suppression of
NF-kappaB activity. We conclude that
sphondin may have the therapeutic potential as an anti-inflammatory
drug on airway
inflammation.